ArticleIn vivo (Athens, Greece)
Up-front Hypofractionated Radiotherapy Before Third-Generation Chemotherapy in Node-positive Breast Cancer: A Retrospective Comparative Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemotherapy Before Radiotherapy in Adjuvant Breast Cancer: The Origins of a Convention and the Case for Revisiting Sequence in the Era of Hypofractionation.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to assess the time advantages of delivering adjuvant hypofractionated radiotherapy (AH-RT) before third-generation adjuvant chemotherapy (A-CT), compared to the standard sequence (A-CT before AH-RT), in node-positive breast cancer (BC). PATIENTS AND
methodsA total of 45 patients with node-positive BC treated with AH-RT before third-generation A-CT at our institution between 2022 and 2023 (EXP group) were retrospectively enrolled and matched with a control group of 45 patients treated with standard sequencing (CTRL group). The primary endpoints were as follows: gain in time to RT initiation and overall treatment time, RT delay, RT interruptions, which were compared between the two groups. Propensity score matching was performed. Univariate and multivariate Cox-proportional hazards models were generated. Data from the multivariate analysis were confirmed by Pearson's covariance test, assuming
resultsA significant reduction in the time to AH-RT initiation and overall adjuvant treatment time was recorded in the EXP group. In the EXP group, the mean duration of the entire adjuvant treatment was 35 (29-40) weeks after surgery vs. 42 (39-50) weeks for the CTRL group (
conclusionTreatment with AH-RT before third-generation A-CT was found to be safe with a low acute toxicity profile in node-positive breast cancer, providing an advantage in shortening the time from surgery to AH-RT initiation as well as the overall adjuvant treatment time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.